ValuEngine Upgrades Bellerophon Therapeutics (NASDAQ:BLPH) to “Sell”

Bellerophon Therapeutics (NASDAQ:BLPH) was upgraded by investment analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a report released on Thursday, ValuEngine reports.

BLPH has been the topic of a number of other research reports. Zacks Investment Research upgraded shares of Bellerophon Therapeutics from a “hold” rating to a “buy” rating and set a $0.75 price target on the stock in a report on Wednesday, May 15th. Maxim Group set a $3.00 price target on shares of Bellerophon Therapeutics and gave the stock a “buy” rating in a report on Monday, April 8th.

Bellerophon Therapeutics stock traded up $0.02 during mid-day trading on Thursday, reaching $0.63. The company had a trading volume of 590,800 shares, compared to its average volume of 275,743. Bellerophon Therapeutics has a fifty-two week low of $0.47 and a fifty-two week high of $2.62. The company has a debt-to-equity ratio of 0.18, a quick ratio of 2.99 and a current ratio of 2.99. The firm has a market cap of $46.14 million, a P/E ratio of -1.85 and a beta of -0.04. The company has a fifty day moving average of $0.64.

Bellerophon Therapeutics (NASDAQ:BLPH) last issued its earnings results on Thursday, May 9th. The biotechnology company reported $0.01 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.11. Sell-side analysts predict that Bellerophon Therapeutics will post -0.21 earnings per share for the current fiscal year.

In other Bellerophon Therapeutics news, Director Theodore T. Wang purchased 50,000 shares of the business’s stock in a transaction dated Wednesday, June 12th. The shares were bought at an average price of $0.64 per share, for a total transaction of $32,000.00. Following the completion of the acquisition, the director now owns 584,479 shares in the company, valued at $374,066.56. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last quarter, insiders have bought 75,000 shares of company stock worth $47,200. 53.10% of the stock is owned by company insiders.

A hedge fund recently bought a new stake in Bellerophon Therapeutics stock. Arch Venture Corp purchased a new position in shares of Bellerophon Therapeutics Inc (NASDAQ:BLPH) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 965,660 shares of the biotechnology company’s stock, valued at approximately $631,000. Bellerophon Therapeutics accounts for 0.6% of Arch Venture Corp’s investment portfolio, making the stock its 5th largest holding. Arch Venture Corp owned 1.40% of Bellerophon Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 54.69% of the company’s stock.

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company, which focuses on developing innovative products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The company engages in two programs including INOpulse and BCM.

Recommended Story: What is a Call Option?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.